Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

被引:57
作者
Hahn, T
Rondeau, C
Shaukat, A
Jupudy, V
Miller, A
Alam, AR
Baer, MR
Bambach, B
Bernstein, Z
Chanan-Khan, AA
Czuczman, MS
Slack, J
Wetzler, M
Mookerjee, BK
Silva, J
McCarthy, PL
机构
[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[2] SUNY Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14260 USA
[3] Dept Pediat Oncol, Buffalo, NY USA
[4] Roswell Pk Canc Inst, Dept Radiat Oncol, Buffalo, NY 14263 USA
关键词
renal failure; stem cell transplantations; toxicity;
D O I
10.1038/sj.bmt.1704144
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of 97 consecutive allogeneic blood and marrow transplantation (alloBMT) patients. In all, 20 (21%) developed Renal BG3 (all died by day + 132) and 77 (79%) developed renal insufficiency (Renal BG1-2). Renal BG3 was a contributing or primary cause of death in 18 (90%) patients who continued to require dialysis at time of death. The two Renal BG3 patients whose deaths were not related to renal failure died on day + 103 of hemorrhage and day + 132 of underlying disease. By univariate analysis, age, unrelated donor, veno-occlusive disease (VOD) and grade III-IV acute graft-versus-host disease with hepatic involvement were significantly associated with Renal BG3. The multivariate model of time to Renal BG3 determined only a prior diagnosis of severe acute GVHD (RR = 4.1, 95% CI 1.6-10.3, P = 0.003) and VOD (RR = 9.1, 95% CI 3.5-23.7, P<0.001) as significant independent predictors. Renal BG3 is generally considered a conditioning regimen-related toxicity. This study demonstrates that Renal BG3 is most commonly a complication of hepatic co-morbidities after allogeneic blood and marrow transplantation and identifies patients with a very poor prognosis.
引用
收藏
页码:405 / 410
页数:6
相关论文
共 26 条
  • [1] Alam A, 1997, BLOOD, V90, P449
  • [2] Alidina A, 1999, Biol Blood Marrow Transplant, V5, P322, DOI 10.1016/S1083-8791(99)70008-X
  • [3] CYCLOSPORIN A ASSOCIATED NEPHROTOXICITY IN THE 1ST 100 DAYS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - 3 DISTINCT SYNDROMES
    ATKINSON, K
    BIGGS, JC
    HAYES, J
    RALSTON, M
    DODDS, AJ
    CONCANNON, AJ
    NAIDOO, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1983, 54 (01) : 59 - 67
  • [4] REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    BEARMAN, SI
    APPELBAUM, FR
    BUCKNER, CD
    PETERSEN, FB
    FISHER, LD
    CLIFT, RA
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1562 - 1568
  • [5] BEARMAN SI, 1994, BONE MARROW TRANSPL, V13, P31
  • [6] HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP
    BROWN, RA
    WOLFF, SN
    FAY, JW
    PINEIRO, L
    COLLINS, RH
    LYNCH, JP
    STEVENS, D
    GREER, J
    HERZIG, RH
    HERZIG, GP
    [J]. BLOOD, 1995, 85 (05) : 1391 - 1395
  • [7] CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE
    CHAO, NJ
    SCHMIDT, GM
    NILAND, JC
    AMYLON, MD
    DAGIS, AC
    LONG, GD
    NADEMANEE, AP
    NEGRIN, RS
    ODONNELL, MR
    PARKER, PM
    SMITH, EP
    SNYDER, DS
    STEIN, AS
    WONG, RM
    BLUME, KG
    FORMAN, SJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (17) : 1225 - 1230
  • [8] LIMITED TOLERANCE OF INTENSIFIED CONDITIONING REGIMENS IN CHILDREN RECEIVING METHOTREXATE CYCLOSPORINE-A FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
    EMMINGER, W
    EMMINGERSCHMIDMEIER, W
    PETERS, C
    HAWLICZEK, R
    HOCKER, P
    GADNER, H
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1992, 9 (01) : 1 - 9
  • [9] Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    Giralt, S
    Thall, PF
    Khouri, I
    Wang, XM
    Braunschweig, I
    Ippolitti, C
    Claxton, D
    Donato, M
    Bruton, J
    Cohen, A
    Davis, M
    Andersson, BS
    Anderlini, P
    Gajewski, J
    Kornblau, S
    Andreeff, M
    Przepiorka, D
    Ueno, NT
    Molldrem, J
    Champlin, R
    [J]. BLOOD, 2001, 97 (03) : 631 - 637
  • [10] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
    GLUCKSBERG, H
    STORB, R
    FEFER, A
    BUCKNER, CD
    NEIMAN, PE
    CLIFT, RA
    LERNER, KG
    THOMAS, ED
    [J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304